Document Detail

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial.
MedLine Citation:
PMID:  20736448     Owner:  NLM     Status:  In-Process    
BACKGROUND: Erythropoietin improves myocardial function in experimental models of myocardial infarction. The aim of the present study was to determine the value of erythropoietin in patients with acute ST-elevation myocardial infarction.
METHODS AND RESULTS: This randomized, double-blind study included 138 patients admitted with acute ST-elevation myocardial infarction and treated with primary percutaneous coronary intervention. Patients were randomly assigned to receive epoetin-β (3.33×104 U, n=68) or placebo (n=70) immediately and at 24 and 48 hours after percutaneous coronary intervention. The primary end point was left ventricular ejection fraction after 6 months measured by MRI. Other end points included infarct size at 5 days and 6 months. Clinical adverse events (death, recurrent myocardial infarction, stroke, and infarct-related artery revascularization) were investigated at 30 days and 6 months. Left ventricular ejection fraction at 6-month follow-up was 52.0±9.1% in the erythropoietin group compared with 51.8±9.3% in the placebo group (P=0.92). Five days after percutaneous coronary intervention, left ventricular ejection fraction was 49.4±8.0% in the erythropoietin group and 50.8±7.3% in the placebo group (P=0.32); infarct size was 26.8±20.9% and 28.3±24.4% (P=0.76) and decreased to 17.3±14.3% and 20.9±16.4% at 6-month follow-up (P=0.27). The cumulative 6-month incidence of death, recurrent myocardial infarction, stroke or target vessel revascularization was 13.2% in the erythropoietin group and 5.7% in the placebo group (hazard ratio, 2.36; 95% confidence interval, 0.73 to 7.66; P=0.15).
CONCLUSIONS: In patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention, erythropoietin treatment did not improve left ventricular ejection fraction or reduce infarct size but may increase clinical adverse events.
CLINICAL TRIAL REGISTRATION: URL: Unique identifier: NCT00390832.
Ilka Ott; Stefanie Schulz; Julinda Mehilli; Stefanie Fichtner; Martin Hadamitzky; Katharina Hoppe; Tareq Ibrahim; Steffan Martinoff; Steffen Massberg; Karl-Ludwig Laugwitz; Josef Dirschinger; Markus Schwaiger; Adnan Kastrati; Albert Schmig;
Related Documents :
3177178 - The clinical and pathophysiologic implications of pain, st abnormalities, and scintigra...
923068 - Predictive implications of ventricular premature contractions associated with treadmill...
16962128 - Electrocardiogram dynamics for risk stratification in st-segment elevation myocardial i...
19556418 - Acute st-segment elevation myocardial infarction associated with diclofenac-induced ana...
23047858 - A navigation platform for guidance of beating heart transapical mitral valve repair.
12147568 - B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital ...
Publication Detail:
Type:  Journal Article     Date:  2010-08-24
Journal Detail:
Title:  Circulation. Cardiovascular interventions     Volume:  3     ISSN:  1941-7632     ISO Abbreviation:  Circ Cardiovasc Interv     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101499602     Medline TA:  Circ Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  408-13     Citation Subset:  IM    
1. Medizinische Klinik rechts der Isar, Munich, Germany.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary artery bypass grafting after recent or remote percutaneous coronary intervention in the Com...
Next Document:  The Platelet Activity After Clopidogrel Termination (PACT) study.